Cancer Research Articles

In response to growing concerns amidst the statewide surge of COVID-19 variants, FCS will require all physicians and team members to be fully vaccinated by October 1, 2021.

The in-house oral oncolytic pharmacy of Florida Cancer Specialists & Research Institute (FCS), known as Rx To Go, has been accredited by the National Association of Boards of Pharmacy® (NABP®) for both specialty pharmacy and digital pharmacy practice.

Medical oncologist James Reeves, MD, a member of the Florida Cancer Specialists & Research Institute (FCS) Clinical Research Team, is co-author of an abstract entitled “Abemaciclib combined with adjuvant endocrine therapy in patients with high risk early breast cancer who received neoadjuvant chemotherapy (NAC).”

Dr. Hugo Davila, who practices urology and minimally-invasive surgery with Florida Healthcare Specialists (FHS), is the lead author of a new study entitled “Evaluation of the Pubocervical Fascia with 3-Dimensional Endovaginal Ultrasonography (EVUS) and Correlation with Intraoperative Findings during Robotic Sacrocervicopexy.”

Lucio Gordan MD, President and Managing Physician of Florida Cancer Specialists & Research Institute (FCS) and Michael Diaz, MD, Assistant Managing Physician of FCS, are two of the authors of a comprehensive and detailed review on the advisability and efficiency of the current reimbursement methodology in use for Medicare Part B. 

Florida Cancer Specialists & Research Institute (FCS) physicians and senior leaders are the co-authors of 32 research studies that will be presented at the American Society of Clinical Oncology (ASCO®)  2021 Annual Meeting being held June 4 – 8, 2021.

Medical oncologist Syed Zafar MD, who practices at three Florida Cancer Specialists & Research Institute (FCS) locations in Lee County, is co-author of a new study entitled “Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.”

Julio Lautersztain, MD, medical oncologist who practices at Florida Cancer Specialists & Research Institute (FCS) locations in Tampa and Brandon, is co-author of a new study entitled “Novel mechanism of hereditary pyropoikilocytosis phenotype due to co‐inheritance of β globin and α spectrin mutations.”